Daiichi Sankyo has announced that Japanese regulators have approved the use of its Inavir laninamivir octanoate hydrate DPI for the prevention of influenza in single doses of 20 mg for children under 10 years old and single doses of 40 mg for anyone older than 10.
Inavir was approved in Japan for the treatment of influenza A and B in 2010 and for the prevention of flu in 2013. The initial approval of Inavir for prevention of flu okayed a daily single dose of 20 mg for 2 days for adults and children over 10 years old; that dosage regimen is still presented as an alternative to the single dose in that age group.
The company said, “The additional dosage regimen approvals of this influenza antiviral agent will allow Daiichi Sankyo to offer a new choice of medicines to all patients and medical personnel, allowing Daiichi Sankyo to further contribute to the health of society.”
Read the Daiichi Sankyo press release.
